ClinicalTrials.gg
TerminatedNCT01545817CATChEzUpdated Oct 9, 2019Results posted

Everolimus Post Pazopanib Treatment in Metastatic or Advanced Renal Cell Carcinoma

A Phase 2 interventional study of Pazopanib followed by everolimus in Carcinoma, Renal Cell, sponsored by Novartis Pharmaceuticals. Terminated at 15 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-10-09.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Why this study was terminated
As the therapeutic landscape in renal cell carcinoma is changing, it has become apparent that information gained so far by CATChEz study is sufficient.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
74
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 45 studies testing pazopanib in Carcinoma, Renal Cell — 1 open to participants now, 4 under way, 1 of them phase 3. pazopanib · Carcinoma, Renal Cell.

Enrollment
16th of 45
74 · median 44
Started
2012
with 8 others
Phase 2
21 of 45
none open now
Registered
25th of 45
by date
Lead sponsor
8 of 45
Novartis Pharmaceuticals

Among the 45 studies testing pazopanib in Carcinoma, Renal Cell, this one is the 16th largest by enrollment, is one of 9 that started in 2012, is one of 21 in phase 2, and was the 25th registered.

Carcinoma, Renal Cell

2,039 studies on the registry are indexed under Carcinoma, Renal Cell; 395 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

1 of the 45 studies testing pazopanib in Carcinoma, Renal Cell is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About pazopanib

pazopanib: first FDA approval 2009 (VOTRIENT), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 307 Carcinoma, Renal Cell studies recruiting now, 254 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 20 take children under 18; 19 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 45 studies testing pazopanib in Carcinoma, Renal Cell, or all of them as a file.
02

Study summary

Study to determine the efficacy, safety and tolerability of first-line pazopanib followed by second-line everolimus in metastatic and advanced renal cell carcinoma.

Due to changes in the RCC treatment landscape, info gained is no longer clinically relevant to patients. Data collected is deemed sufficient to meet objective.

Read the detailed description

A non-randomised, open label, single-arm phase II study to evaluate the efficacy and safety of 1st-line pazopanib followed by 2nd-line everolimus in patients with previously untreated advanced or metastatic renal cell carcinoma. Subjects received initial therapy with pazopanib followed, on progression, by 2nd-line therapy with everolimus. Study treatment - sequential treatment with pazopanib followed by everolimus - to continue until disease progression, unacceptable toxicity, withdrawal of consent, or death.

03

Conditions studied

  • Carcinoma, Renal Cell

Keywords

  • Renal cell carcinoma (RCC), GW786034, Everolimus, Pazopanib, renal cancer, cancer, kidney cancer, hypernephroma, Grawitz tumor, renal adenocarcinoma.
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age >=18 years
  • confirmed RCC with a clear-cell component
  • Locally advanced or RCC
  • At least one per 1.1 criteria, as determined by Computer Tomography (CT) Scan or Magnetic Resonance Imaging (MRI)
  • No systemic therapy for advanced or metastatic RCC prior to enrollment
  • Performance Status (KPS) ≥70
  • Adequate baseline organ function
  • A female was eligible to enter and participate in this study if she was of: non-, or negative serum pregnancy test with agreement to use adequate during the study
  • A male with female partner of childbearing potential must have vasectomy/agree to use effective contraception from 2 weeks prior to administration of the 1st dose of study treatment for a period of time after the last dose of study treatment
  • Able to swallow and retain orally administered medication and must not have GI abnormalities that may alter absorption

Additional inclusion criteria for starting everolimus:

  • Disease progression must be within 6 months after stopping pazopanib
  • At least one measurable lesion at the start of everolimus pe r RECIST 1.1 criteria, as determined by CT or MRI
  • In case of central nervous system (CNS) progression or metastasis during pazopanib treatment: asymptomatic or neurologically stable, no requirement of to control CNS symptoms, and no requirement of enzyme-inducing anticonvulsants within 4 weeks prior to the start of everolimus

Exclusion criteria

Exclusion Criteria:

  • Lactating female
  • History of another (exception: patients disease-free for ≥3 years and patients with completely resected non-melanoma skin cancer or successfully treated in situ carcinoma)
  • Symptomatic at baseline
  • gastrointestinal abnormalities
  • Moderate to severe hepatic impairment ( Class C)
  • Receiving chronic treatment with /other agents
  • Active bleeding, bleeding diathesis or on oral anti-vitamin K medication (except low dose coumadin)
  • interval (QTc) >480 msec using Bazett's formula
  • Presence of any severe or uncontrolled medical conditions/infection
  • Poorly controlled hypertension (defined as systolic blood pressure of >=140mmHg or diastolic blood pressure of >=90mmHg)
  • History of cardiovascular disorders within the last 12 months (e.g. myocardial infraction or unstable angina), history of cerebrovascular events or pulmonary embolism within the last 6 months
  • Active bleeding or bleeding susceptibility
  • Known endobronchial lesion and/or lesions infiltrating major pulmonary vessels that increased the risk of pulmonary hemorrhage

Additional criteria for exclusion from the everolimus treatment period:

  • The subject felt by the investigator to be unsuitable (on the basis of health, compliance, or for any other reason) for inclusion in the study.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Masking
None (open label)
Enrollment
74 participants (actual)

Study arms

  • Experimental
    Pazopanib followed by everolimus

    First line pazopanib, followed by second line everolimus

    Drug: Pazopanib followed by everolimus

Interventions

  • DrugPazopanib followed by everolimus

    Drug pages: Pazopanib · Everolimus

    All patients received Pazopanib (800 mg once daily orally continuous dosing) until disease progression then second line everolimus (10 mg once daily orally continuous dosing)

    Also known as: Pazopanib 1st line followed by everolimus 2nd line

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS) for the Everolimus Treatment Period Using RECIST

    Time between the date of first everolimus dose and date of disease progression or death (whichever comes first) in patients treated initially with pazopanib. Disease progression is measured by RECIST (Response Evaluation Criteria in Solid Tumors), which is at least a 20% increase in the sum of the target lesion longest diameters (LDs).

    Time frame: Throughout the study period, up to 4 years

Secondary outcomes

  1. Progression Free Survival (PFS) Rates

    PFS rates 3 and 6 months after date of first dose of second-line everolimus treatment.

    Time frame: 3 months, 6 months

  2. Objective Response Rate (ORR) for the Everolimus Treatment Period Using RECIST

    Percentage of patients with Complete or Partial Response at any time following the start of second-line everolimus treatment as per RECIST. RECIST Complete Response is defined to be a disappearance of all target lesion(s). RECIST Partial Response is defined to be at least a 30% decrease in the sum of the target lesion LDs.

    Time frame: Throughout the study, up to 4 years

  3. Objective Response Rate (ORR) for the Pazopanib Treatment Period Using RECIST

    Percentage of patients with Complete or Partial Response at any time following the start of first-line pazopanib treatment. RECIST Complete Response is defined to be a disappearance of all target lesion(s). RECIST Partial Response is defined to be at least a 30% decrease in the sum of the target lesion LDs.

    Time frame: Throughout the study period, up to 4 years

  4. Overall Survival of Everolimus (OSE)

    Time from first everolimus dose until death due to any cause

    Time frame: Throughout the study period, up to 4 years

  5. Overall Survival From the Start (OSS) of Study Treatment

    Time from first pazopanib dose until death due to any cause in patients who received at least one dose of pazopanib followed by everolimus

    Time frame: Throughout the study, up to 4 years

  6. PFS for the Pazopanib Treatment Period Using RECIST

    Time from first pazopanib dose until disease progression or death from any cause (whichever occurred earlier), provided this occurred prior to the start of everolimus and within 6 months of last dose of pazopanib

    Time frame: Throughout the study period, up to 4 years

07

Results

Posted Oct 9, 2019
Limitations and caveats
the trial terminated early because the information gained from this study was sufficient to meet the objectives for which the study had been set up and would be no longer clinically relevant for the second-line management of RCC patients.

Participant flow

A total of 74 patients were enrolled, all started first-line pazopanib treatment. Of these, 51 discontinued pazopanib and 38 continued to second-line everolimus treatment

Pazopanib
Participant flow — Pazopanib
MilestonePazopanibEverolimus
Started740
Completed00
Not completed740
Withdrew: Disease progression510
Withdrew: Adverse event190
Withdrew: Other reason40
Everolimus
Participant flow — Everolimus
MilestonePazopanibEverolimus
Started038
Completed00
Not completed038
Withdrew: Other reason07
Withdrew: Disease progression025
Withdrew: Adverse event06

Outcome measures

PrimaryProgression Free Survival (PFS) for the Everolimus Treatment Period Using RECIST

Time between the date of first everolimus dose and date of disease progression or death (whichever comes first) in patients treated initially with pazopanib. Disease progression is measured by RECIST (Response Evaluation Criteria in Solid Tumors), which is at least a 20% increase in the sum of the target lesion longest diameters (LDs).

Time frame:
Throughout the study period, up to 4 years
Reported as:
Median · months
Progression Free Survival (PFS) for the Everolimus Treatment Period Using RECIST
monthsEverolimus
Progression Free Survival (PFS) for the Everolimus Treatment Period Using RECIST5.1 (3.4 to 6.8)
SecondaryProgression Free Survival (PFS) Rates

PFS rates 3 and 6 months after date of first dose of second-line everolimus treatment.

Time frame:
3 months, 6 months
Reported as:
Number · Survival probability
Progression Free Survival (PFS) Rates
Survival probabilityAll Patients
3 months0.737 (0.554 to 0.854)
6 months0.355 (0.196 to 0.517)
SecondaryObjective Response Rate (ORR) for the Everolimus Treatment Period Using RECIST

Percentage of patients with Complete or Partial Response at any time following the start of second-line everolimus treatment as per RECIST. RECIST Complete Response is defined to be a disappearance of all target lesion(s). RECIST Partial Response is defined to be at least a 30% decrease in the sum of the target lesion LDs.

Time frame:
Throughout the study, up to 4 years
Reported as:
Number · Percentages of Participants
Objective Response Rate (ORR) for the Everolimus Treatment Period Using RECIST
Percentages of ParticipantsAll Patients
Complete response0.0 (0.00 to 9.3)
Partial response7.9 (1.7 to 21.4)
SecondaryObjective Response Rate (ORR) for the Pazopanib Treatment Period Using RECIST

Percentage of patients with Complete or Partial Response at any time following the start of first-line pazopanib treatment. RECIST Complete Response is defined to be a disappearance of all target lesion(s). RECIST Partial Response is defined to be at least a 30% decrease in the sum of the target lesion LDs.

Time frame:
Throughout the study period, up to 4 years
Reported as:
Number · Percentages of participants
Objective Response Rate (ORR) for the Pazopanib Treatment Period Using RECIST
Percentages of participantsAll Patients
Complete response6.8 (2.2 to 15.1)
Partial response39.2 (28.0 to 51.2)
SecondaryOverall Survival of Everolimus (OSE)

Time from first everolimus dose until death due to any cause

Time frame:
Throughout the study period, up to 4 years
Reported as:
Median · months
Overall Survival of Everolimus (OSE)
monthsEverolimus
Overall Survival of Everolimus (OSE)15.6 (9.9 to 25.3)
SecondaryOverall Survival From the Start (OSS) of Study Treatment

Time from first pazopanib dose until death due to any cause in patients who received at least one dose of pazopanib followed by everolimus

Time frame:
Throughout the study, up to 4 years
Reported as:
Median · Months
Overall Survival From the Start (OSS) of Study Treatment
MonthsPazopanib
Overall Survival From the Start (OSS) of Study Treatment35.7 (26.7 to NA)
SecondaryPFS for the Pazopanib Treatment Period Using RECIST

Time from first pazopanib dose until disease progression or death from any cause (whichever occurred earlier), provided this occurred prior to the start of everolimus and within 6 months of last dose of pazopanib

Time frame:
Throughout the study period, up to 4 years
Reported as:
Number · Months
PFS for the Pazopanib Treatment Period Using RECIST
MonthsPazopanib
PFS for the Pazopanib Treatment Period Using RECIST11.0 (7.2 to 14.8)

Adverse events

Collected over Adverse events for each intervention were assessed from the time of first dose of treatment to approximately one month after discontinuation of the last dose of treatment, up to 4 years.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pazopanib5/74 (6.8%)47/74 (63.5%)73/74 (98.6%)
Everolimus3/38 (7.9%)16/38 (42.1%)34/38 (89.5%)
Most frequent serious events
Showing 10 of 79
Most frequent serious events
EventPazopanibEverolimus
PneumoniaInfections and infestations2/744/38
Alanine Aminotransferase IncreasedInvestigations6/740/38
Mucosal InflammationGeneral disorders0/742/38
VomitingGastrointestinal disorders2/740/38
GastroenteritisInfections and infestations2/740/38
Back PainMusculoskeletal and connective tissue disorders2/740/38
DyspnoeaRespiratory, thoracic and mediastinal disorders2/740/38
Pleural EffusionRespiratory, thoracic and mediastinal disorders2/741/38
AnaemiaBlood and lymphatic system disorders1/741/38
DuodenitisGastrointestinal disorders0/741/38
Most frequent other events
Showing 10 of 79
Most frequent other events
EventPazopanibEverolimus
DiarrhoeaGastrointestinal disorders45/741/38
FatigueGeneral disorders44/744/38
NauseaGastrointestinal disorders37/746/38
HypertensionVascular disorders24/740/38
Decreased AppetiteMetabolism and nutrition disorders20/745/38
DysgeusiaNervous system disorders18/742/38
AnaemiaBlood and lymphatic system disorders3/749/38
VomitingGastrointestinal disorders17/745/38
Hair Colour ChangesSkin and subcutaneous tissue disorders17/740/38
CoughRespiratory, thoracic and mediastinal disorders16/747/38

Baseline characteristics

All Treated Subjects (ATS) population included all patients who received at least one dose of pazopanib.

Age, Continuous
Age, Continuous(Years)All Patients
Mean66.0 ± 10.68
Sex: Female, Male
Sex: Female, Male(Participants)All Patients
Female20
Male54
08

Study locations

15 sites
  • Novartis Investigative Site
    Garran, Australian Capital Territory 2606, Australia
  • Novartis Investigative Site
    Kogarah, New South Wales 2217, Australia
  • Novartis Investigative Site
    Auchenflower, Queensland 4066, Australia
  • Novartis Investigative Site
    Southport, Queensland 4215, Australia
  • Novartis Investigative Site
    Elizabeth Vale, South Australia 5112, Australia
  • Novartis Investigative Site
    Kurralta Park, South Australia 5037, Australia
  • Novartis Investigative Site
    Woodville, South Australia 5011, Australia
  • Novartis Investigative Site
    Footscay, Victoria 3011, Australia
  • Novartis Investigative Site
    Frankston, Victoria 3199, Australia
  • Novartis Investigative Site
    Nedlands, Western Australia 6009, Australia
  • Novartis Investigative Site
    Perth, Western Australia 6001, Australia
  • Novartis Investigative Site
    Gyeonggi-do, 10408, Korea, Republic of
  • Novartis Investigative Site
    Seoul, 03080, Korea, Republic of
  • Novartis Investigative Site
    Seoul, 135-710, Korea, Republic of
  • Novartis Investigative Site
    Seoul, 138-736, Korea, Republic of
09

References and documents

Individual participant data

Plan to share: Undecided — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2012 to primary completion in Nov 2016, 54 months.

Results were first posted in Oct 2019, 2 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2011
First posted
Mar 7, 2012
StartActual
Apr 19, 2012
Primary completionActual
Nov 18, 2016
CompletionActual
Nov 18, 2016
Results first posted
Oct 9, 2019
Last update
Oct 9, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 9, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01545817
Responsible party
Sponsor
First posted
Mar 7, 2012
Start date
Apr 19, 2012
Primary completion
Nov 18, 2016
Completion
Nov 18, 2016
Results posted
Oct 9, 2019
Last update
Oct 9, 2019

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pazopanib · Everolimus

Start the discussion